Active Biotech AB Year-end report January - December 2015

| Source: Active Biotech Active Biotech

LUND, Sweden, Feb. 18, 2016 (GLOBE NEWSWIRE) --

Laquinimod

  • In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod's potential for treatment of primary progressive multiple sclerosis (PPMS)
  • In June, it was announced that the company was to focus its operations on the laquinimod projects and adjust the organization accordingly
  • In June, it was announced that the Phase 3 laquinimod study CONCERTO was fully enrolled
  • In October, Teva presented data concerning laquinimod for the treatment of multiple sclerosis at the ECTRIMS congress
  • The high dose group in the clinical studies CONCERTO, ARPEGGIO and LEGATO has been discontinued due to cardiovascular events
  • The study results from both the pivotal clinical Phase 3 study CONCERTO in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017

Tasquinimod

  • In April, it was announced that Active Biotech and Ipsen were to discontinue development of tasquinimod for the treatment of prostate cancer
  • The final results from the 10TASQ10 study were presented in September 2015 at the ECC conference and demonstrated that while the primary endpoint was reached and tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS

ANYARA, Paquinimod (57-57) and ISI

  • Out-licensing activities are continuing

Financial summary

MSEK Oct - Dec     Jan. - Dec.  
  2015 2014   2015 2014  
             
Net sales 5.0 2.9   16.3 10.4  
             
Operating loss -28.2 -55.6   -177.9 -228.5  
             
Loss for the period -40.8 -57.0   -193.5 -231.5  
             
Loss per share, before and after dilution (SEK) -0.45 -0.73   -2.15 -3.02  
             
Cash and cash equivalents        103.6 328.5  


For further information, please contact: 
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
  
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
      

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
                                                                 
The report is also available at www.activebiotech.com.

Active Biotech AB Year-end report January - December 2015 http://hugin.info/1002/R/1986986/729147.pdf

HUG#1986986